Genmab's petosemtamab cuts death risk by 50% in head and neck cancer Phase 3 LiGeR-HN1 study

Genmab announced data from its Phase 3 LiGeR-HN1 study showing petosemtamab demonstrates a 50% reduction in death risk for the treatment of head and neck squamous cell carcinoma.

Detected & updated continuously · Source: Nebula